Prognostic markers in triple‐negative breast cancer
暂无分享,去创建一个
Ian O Ellis | I. Ellis | A. Green | E. Rakha | J. Robertson | Andrew H. S. Lee | Andrew R Green | Maysa E El-Sayed | Emad A Rakha | Maysa E El-Sayed | Andrew H S Lee | John F Robertson | M. E. El-Sayed | A. Green
[1] D. Cosgrove. The breast , 1999, European Radiology.
[2] François Vaillant,et al. Steroid hormone receptor status of mouse mammary stem cells. , 2006, Journal of the National Cancer Institute.
[3] S. Schnitt,et al. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer , 2006, Modern Pathology.
[4] M. Hung,et al. Dysregulation of cellular signaling by HER2/neu in breast cancer. , 2003, Seminars in oncology.
[5] G. Ball,et al. High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.
[6] C. Isaacs,et al. Prognostic Factors in Breast Cancer: Current and New Predictors of Metastasis , 2001, Journal of Mammary Gland Biology and Neoplasia.
[7] Shousha,et al. Adenoid cystic carcinoma of the breast: a tumour commonly devoid of oestrogen receptors and related proteins , 1999, Histopathology.
[8] S. Shousha,et al. Morphologic spectrum of estrogen receptor-negative breast carcinoma. , 2002, Archives of pathology & laboratory medicine.
[9] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[10] Ian O Ellis,et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis , 2005, Modern Pathology.
[11] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[12] B. Moon,et al. Secretory carcinoma of the breast , 2003, Journal of clinical ultrasound : JCU.
[13] J. Robertson,et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation , 2006, The Journal of pathology.
[14] Paul E Swanson,et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. , 2003, American journal of clinical pathology.
[15] A. Bednarek,et al. Prognostic Relevance of Basal Cytokeratin Expression in Operable Breast Cancer , 2006, Oncology.
[16] S. Takekoshi,et al. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression. , 2005, Oncology reports.
[17] I. Ellis,et al. Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.
[18] D. Fouskakis,et al. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients. , 2004, Anticancer research.
[19] I. Ellis,et al. The prognosis of small primary breast cancers. , 1999, European journal of cancer.
[20] C. Benz,et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies , 2006, Molecular Cancer.
[21] I. Ellis,et al. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma , 2004, British Journal of Cancer.
[22] F. Melsen,et al. Prognostic comparison of three classifications for medullary carcinomas of the breast , 1997, Histopathology.
[23] M. Piccart,et al. An overview of HER2. , 2001, Seminars in oncology.
[24] J. Nesland,et al. The prognostic value of p53 and c‐erb b‐2 immunostaining is overrated for patients with lymph node negative breast carcinoma , 2000, Cancer.
[25] W. Bezwoda. C-erb-B2 expression and response to treatment in metastatic breast cancer , 2000, Medical oncology.
[26] R. Tibshirani,et al. Copyright © American Society for Investigative Pathology Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome , 2022 .
[27] W D Dupont,et al. Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading , 1984, Cancer.
[28] Qifeng Yang,et al. Predictive and prognostic markers for invasive breast cancer , 2002, Pathology international.
[29] M. Kimmel,et al. Estrogen Receptor Protein of Breast Cancer in Patients With Positive Nodes: High Recurrence Rates in the Postmenopausal Estrogen Receptor—Negative Group , 1987 .
[30] D. Rimm,et al. Validation of Tissue Microarray Technology in Breast Carcinoma , 2000, Laboratory Investigation.
[31] A. Dursun,et al. The Prognostic Value of p53 and c-erbB-2 Expression, Proliferative Activity and Angiogenesis in Node-Negative Breast Carcinoma , 2005, Tumori.
[32] I. Ellis,et al. The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.
[33] B. Asselain,et al. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. , 1996, British Journal of Cancer.
[34] G. Moreno-Bueno,et al. The Prognostic Significance of P-Cadherin in Infiltrating Ductal Breast Carcinoma , 2001, Modern Pathology.
[35] Ash A. Alizadeh,et al. Towards a novel classification of human malignancies based on gene expression patterns , 2001, The Journal of pathology.
[36] B. Gusterson,et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[38] C. Perou,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.
[39] L. Hartmann,et al. Prognostic value of c‐erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol , 1994, Cancer.
[40] T. H. van der Kwast,et al. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. , 1996, European journal of cancer.
[41] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[42] I. Ellis,et al. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.
[43] M. Piccart,et al. HER2/neu as a predictive factor in breast cancer. , 2001, Clinical breast cancer.
[44] R. Blamey,et al. E-cadherin as a prognostic indicator in primary breast cancer , 2001, British Journal of Cancer.
[45] Donald E. Henson,et al. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989 .
[46] M. Dowsett,et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[47] R. Moll,et al. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas , 1998, Virchows Archiv.